ROYALTY PHARMA PLC

(RPRX)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 11-08-2022
43.70 USD   -0.50%
08/08ROYALTY PHARMA PLC : Morgan Stanley herhaalt koopadvies
MM
05/08ROYALTY PHARMA PLC : Goldman Sachs herhaalt koopadvies voor het aandeel
MM
04/08Royalty Pharma Q2 netto-inkomen, inkomsten dalen
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť ROYALTY PHARMA PLC
04/08ROYALTY PHARMA PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
04/08ROYALTY PHARMA : Q2 Earnings Snapshot
AQ
04/08Royalty Pharma Reports Second Quarter 2022 Results
GL
04/08Royalty Pharma Reports Second Quarter 2022 Results
AQ
18/07Royalty pharma declares third quarter 2022 dividend
AQ
15/07Royalty Pharma Declares Third Quarter 2022 Dividend
GL
15/07Royalty Pharma Declares Third Quarter 2022 Dividend
AQ
14/07Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022
GL
14/07Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022
AQ
14/07Royalty pharma agrees to acquire royalty interest in trelegy ellipta from theravance an..
AQ
13/07ROYALTY PHARMA : AGREES TO ACQUIRE ROYALTY INTEREST IN TRELEGY ELLIPTA FROM THERAVANCE AND..
PU
13/07ROYALTY PHARMA PLC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
13/07Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance an..
GL
13/07Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Ap..
PR
30/06Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to ..
GL
30/06Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to ..
AQ
30/06Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collabor..
PR
30/06Fitch Affirms Royalty Pharma at 'BBB-'; Outlook Stable
AQ
23/06ROYALTY PHARMA PLC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
08/06Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
GL
23/05Royalty Pharma to Present at the UBS Global Healthcare Conference 2022
GL
23/05Royalty Pharma to Present at the UBS Global Healthcare Conference 2022
AQ
18/05Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Uni..
AQ
17/05Royalty pharma announces charitable alliance with mount sinai
AQ
17/05ROYALTY PHARMA PLC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
17/05Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Uni..
GL
17/05Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Uni..
AQ
11/05ROYALTY PHARMA PLC : Other Events (form 8-K)
AQ
05/05ROYALTY PHARMA PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
05/05ROYALTY PHARMA : Q1 Earnings Snapshot
AQ
05/05Royalty Pharma Reports First Quarter 2022 Results
GL
18/04Royalty Pharma Declares Second Quarter 2022 Dividend
GL
15/04ROYALTY PHARMA PLC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
13/04Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022
AQ
04/04ROYALTY PHARMA PLC : Changes in Registrant's Certifying Accountant, Financial Statements a..
AQ
29/03Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS)..
PR
17/03Can We Finally Advance? CJEU Asked Once Again To Consider SPC Eligibility Of Patents Fo..
AQ
08/03FURTHER REFERRAL TO THE CJEU ON COMB : Concerning Article 3(a) And Article 3(c)
AQ
03/03ROYALTY PHARMA : to Present at Cowen's 42nd Annual Health Care Conference
PU
03/03Royalty Pharma to Present at Cowen's 42nd Annual Health Care Conference
GL
16/02Royalty Pharma Announces Inaugural Investor Day
GL
15/02ROYALTY PHARMA PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
15/02ROYALTY PHARMA : Q4 Earnings Snapshot
AQ
15/02Royalty Pharma Reports Q4 and Full Year 2021 Results
AQ
20/01Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on Febru..
AQ
10/01Royalty pharma and cytokinetics announce funding agreements totaling up to $450 million
AQ
10/01MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guida..
AQ
10/01ROYALTY PHARMA : HIGHLIGHTS ACCOMPLISHMENTS AND PROVIDES BUSINESS UPDATE AT 40TH ANNUAL J...
PU
10/01Royalty Pharma Highlights Accomplishments and Provides Business Update at 40th Annual J..
AQ
07/01Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million
GL
06/01Royalty Pharma Announces 12% Dividend Increase
AQ
05/01Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 10
AQ
2021Royalty Pharma plc announced that it is scheduled to participate in a fireside chat at ..
AQ
2021Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
AQ
2021Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCr..
AQ
2021ROYALTY PHARMA PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
2021ROYALTY PHARMA : Q3 Earnings Snapshot
AQ
2021Royalty Pharma Reports Third Quarter 2021 Results
AQ
2021ROYALTY PHARMA V BOEHRINGER : The UK's Patents Court Takes On The German Law Of Licence Ne..
AQ
2021ROYALTY PHARMA : to Announce Third-Quarter 2021 Financial Results on November 10, 2021
AQ
2021ROYALTY PHARMA : Declares Fourth-Quarter 2021 Dividend
GL
2021ROYALTY PHARMA : To present at upcoming investor conferences
AQ
2021ROYALTY PHARMA : to Present at Upcoming Investor Conferences
AQ
2021ROYALTY PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
2021ROYALTY PHARMA : Q2 Earnings Snapshot
AQ
2021ROYALTY PHARMA : Reports Second Quarter 2021 Results
AQ
2021ROYALTY PHARMA PLC : Entry into a Material Definitive Agreement, Other Events, Financial S..
AQ
2021ROYALTY PHARMA : to Announce Second-Quarter 2021 Financial Results on August 11, 2021
AQ
2021ROYALTY PHARMA : Declares third-quarter 2021 dividend
AQ
2021MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,3..
AQ
2021ROYALTY PHARMA : UNDERWRITING AGREEMENT $1,300,000,000 (Form 8-K)
PU
2021ROYALTY PHARMA PLC : Entry into a Material Definitive Agreement, Financial Statements and ..
AQ
2021MorphoSys AG
AQ
2021Royalty Pharma Declares Third-Quarter 2021 Dividend
GL
2021Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $..
GL
1  2Volgende
Volgende evenement op ROYALTY PHARMA PLC